Article Text
Abstract
This narrative ethics exploration stems from my happy prostate-specific antigen (PSA) story, though it should not have been, as I annually refuse my family physician’s recommendation to purchase PSA screening. The reason for my refusal is I teach ethics to medical students and of course must walk the talk, and PSA screening is not publicly funded in the province of Ontario, Canada. In addition, I might have taken false comfort in ‘but all you need is a good index finger’ to detect prostate cancer, expounded by a senior physician at a national medical conference in 2010, and applauded by the large audience of physicians. I was compelled to begin this exploration out of survivor guilt, although I will not be a survivor for long, and as a mea culpa to the men similarly situated to me in having late diagnosis of prostate cancer, aggressive tumours and multiple metastases, but who unlike me are dead because they did not experience the physician–educator-based exceptionisms and coincidences that permit me to still be alive. Although my PSA story will always be a happy story, even when my life ends in a few years, the initiation of public funding of PSA screening for all men over 50 would make my PSA story an even happier story.
- distributive Justice
- ethics
Statistics from Altmetric.com
Linked Articles
Read the full text or download the PDF:
Other content recommended for you
- Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline
- A Community Jury on PSA screening: what do well-informed men want the government to do about prostate cancer screening—a qualitative analysis
- Do men with lower urinary tract symptoms have an increased risk of advanced prostate cancer?
- Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis
- Primary goals, information-giving and men’s understanding: a qualitative study of Australian and UK doctors’ varied communication about PSA screening
- Prostate cancer screening and the management of clinically localized disease
- Screening for prostate cancer remains controversial
- Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening
- Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study
- Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study